Medication 2 | National Headache Foundation

Allow Migraine Patients and Primary Care Providers to Set Care Plans – NOT INSURERS

Add your name to the NHF’s petition if you agree that insurance companies should adopt care models that are patient-centric, where the clinician, in collaboration with the patient, is the primary decision-maker and selects a treatment that addresses the patient’s…

Heads UP – Episode 112: Access to Care

For too long, migraine patients have been treated differently than others with medical issues as it relates to access to prescription medications. The National Headache Foundation advocates that payers adopt care models that are patient-centric, where the clinician, in…

NHF Calls on Congress and Federal Agencies to Conduct Oversight Of Current Care Models for Migraine Patients

Chicago, Ill. (Feb. 3, 2022) – Tom Dabertin, Chief Executive Officer/Executive Director of the National Headache Foundation (NHF) is calling on members of Congress and regulatory agencies to conduct oversight of health insurance payers for uneven treatment of migraine patients. On…

National Headache Foundation Position Statement on the Treatment of Migraine and Access to Care

January 19, 2022 For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine. For too long, migraine patients have been treated differently than others with medical…

NHF Challenges Current Care Models for Migraine Patients

Older Prescription Drugs in a Stepwise Approach Needs Health Insurance Overhaul Chicago, Ill. (Jan. 19, 2022) – The National Headache Foundation issued a statement challenging health insurance payers for uneven treatment of migraine patients, arguing “current care models have not…

Heads UP – Episode 109: DATA Alert on Intranasal Zavegepant

New Data Alert on the Up-and-Coming Migraine Medication: Intranasal Zavegepant. While not yet approved for release, intranasal zavegepant has shown promise in some interesting and unique data points in the relief of acute migraine. What is zavegepant and what will…

Staying Safe and Healthy During Cold and Flu Season

Getting sick is always an unwelcome disruption to our daily lives. Many of us use acetaminophen to treat our pain or fever symptoms—even if we don’t realize it. Acetaminophen is found in more than 600 over-the-counter (OTC) and prescription medicines….

Heads UP – Episode 103: Atogepant and Migraine

Atogepant (QULIPTA) was just approved by the FDA as a daily oral preventive treatment for migraine. On this episode of Heads UP, Dr. Lindsay Weitzel asks migraine clinical trial expert Dr. Tim Smith all the hard questions: Can we take…

QULIPTA Approved by the FDA for Preventitive Treatment of Migraine

The U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults. QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of…

Heads UP – Episode 101: Trudhesa Nasal Spray for the Acute Treatment of Migraine

Dr. Lindsay Weitzel talks to Dr. Tim Smith about the specifics of Trudhesa, the first DHE nasal spray to utilize Precision Olfactory Delivery (POD) technology. Trudhesa was just approved by the FDA. When will it be available to us? How…

New and Emerging Migraine Medications

I find this to be the most interesting time of year for me to be writing this particular article. This is because of the spring flowers blooming outside right now. The flowers have special meaning to me when it comes…

‹ Previous